Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

16
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
16
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lesion network localization of depression in multiple sclerosis.

Nature. Mental health·2026
Same author

Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adults.

Nature communications·2026
Same author

A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.

Blood advances·2026
Same author

Assessment of the impact of outcome definitions on power in multiple sclerosis clinical trials.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2026
Same journal

Impact of Usual-Care Physiotherapy on Physical Activity and Self-Efficacy in People With Multiple Sclerosis: An Observational Longitudinal Study.

International journal of MS care·2025
Same journal

You've Got a Friend in Me: The Importance of a Confidant and Its Role on Health and Well-Being Among Women With Multiple Sclerosis.

International journal of MS care·2025
Same journal

Understanding Diverse Caregiver Experiences and Their Impact on Caregiver Burden in Multiple Sclerosis.

International journal of MS care·2025
Same journal

Integrating Clinical Pharmacy Services Into Comprehensive Multiple Sclerosis Care Teams: A Narrative Review of 4 Models.

International journal of MS care·2025
Same journal

Current Practices, Challenges, and Future Directions in Multiple Sclerosis Management in Sub-Saharan Africa.

International journal of MS care·2025
Same journal

Resilience Indirectly Affects Functional Capabilities Through Physical Activity Engagement in Individuals With Multiple Sclerosis.

International journal of MS care·2025
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Treatment satisfaction in multiple sclerosis.

Bonnie I Glanz1, Alexander Musallam1, David J Rintell1

  • 1Department of Neurology, Harvard Medical School, Boston, MA, USA (BIG, DJR, TC, HLW, BCH); Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA (BIG, AM, DJR, TC, HLW, BCH); and Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA (BCH).

International Journal of MS Care
|July 26, 2014
PubMed
Summary
This summary is machine-generated.

Treatment satisfaction with multiple sclerosis (MS) therapies, including interferon beta-1a (IFNβ-1a) and glatiramer acetate (GA), showed no overall significant differences. Natalizumab (NTZ) offered greater satisfaction in disease management and convenience.

More Related Videos

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

19.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

191

Related Experiment Videos

Last Updated: Apr 26, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

19.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:19

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

191

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Disease-modifying therapies (DMTs) for multiple sclerosis (MS) often present challenges with administration, side effects, and adherence.
  • Patient satisfaction is a critical factor in long-term treatment adherence and outcomes.

Purpose of the Study:

  • To compare treatment satisfaction among MS patients using different DMTs: intramuscular interferon beta-1a (IFNβ-1a IM), subcutaneous interferon beta-1a (IFNβ-1a SC), glatiramer acetate (GA), and natalizumab (NTZ).
  • To investigate the relationship between treatment satisfaction and therapy adherence.

Main Methods:

  • A cohort of 226 treated MS patients completed the Treatment Satisfaction Questionnaire for Medicine.
  • Multivariable models were employed to analyze and compare treatment satisfaction scores across the different DMT groups.

Main Results:

  • No statistically significant differences were observed in overall treatment satisfaction across the DMT groups.
  • Natalizumab (NTZ) users reported higher satisfaction with the medication's efficacy in treating/preventing MS compared to IFNβ-1a IM.
  • NTZ demonstrated superior convenience and ease of use compared to IFNβ-1a IM, and greater ease of use than interferon and GA groups.
  • Lower convenience scores correlated with lower adherence in IFNβ-1a SC and GA treated patients.

Conclusions:

  • While overall satisfaction was similar, specific DMTs like natalizumab offer advantages in perceived efficacy and convenience.
  • Treatment convenience is linked to adherence for certain DMTs, such as IFNβ-1a SC and GA.
  • Findings can inform shared decision-making between MS patients and healthcare providers regarding DMT selection.